. We also analyzed survival and compared our data with that reported in the literature. Methods: Clinical and demographic characteristics were analyzed for the entire series and trends were compared by year of diagnosis. Changes in epidemiology were examined and compared. Results: There were 701 patients (91.4% were men, mean age 67.6). Main histology was squamous cell carcinoma (41.5%). Squamous cell carcinoma prevailed in men (45.5%) and adenocarcinoma (ADC) in women (60.3%). The percentage of men with lung cancer and of patients with squamous cell carcinoma was higher than in the reported worldwide data and remained throughout the 10 years period. Mean survival was low, with < 10% survivors at 5 years. Stage of disease remained the main prognostic factor for survival. Conclusion: Squamous cell carcinoma continues to be the most frequent histological type in our area. Male and smoking is associated with lung carcinoma while ADC more often occurs in females. Over the time, our epidemiological and histological patterns have not changed, possibly in relation to maintenance of smoking habits.
Introduction
Epidemiological changes in smoking habits are affecting the pattern of lung cancer patients, with perhaps an increasing number of non-smokers, women involved, and variation in the occurrence of adenocarcinoma (ADC). [1] [2] [3] Despite treatment advances in lung cancer, it continues to be one of the most lethal cancers worldwide.
Lung cancer still ranks as the leading cause of tumor-related death in the world. [1] Some important epidemiological factors are age, gender and histology, and these have markedly changed in the past few years. [4] Reasons could be non-smoking policies, population aging, women now smoking, improvement in histological and imaging diagnosis, etc. [2] [3] [4] [5] [6] The patterns of change vary, mainly given the heterogeneity of smoking habits in different countries. There is scattered information available concerning the various epidemiological and clinical aspects of lung cancer today, especially in Spain and in daily clinical practice. [7] In order to describe how lung cancer patients are managed at our regional hospital, since 2004, all such patients who were seen at our outpatient oncology unit were prospectively registered into a hospital-based cancer registry. The aim of the present review is to describe their epidemiologic characteristics, focusing on gender, histology and stage. Trends through years were also analyzed.
The primary objective was to describe the lung cancer characteristics of patients followed for up to 10 years, from 2004 to 2014, and to study the evolution of the disease over these years. In addition, we herein describe their epidemiologic characteristics, correlations, and prognostic factors through these years.
Methods

Patients and methods
This was a single-center study, prospectively performed at the Medical Oncology Unit of our hospital. All patients seen by our medical consultation (not all with a diagnosis of lung cancer) were prospectively included in our database registry. During the study period, our hospital served a predominantly rural community, with a population of about 210,000 in which geographic mobility was low. Our lung cancer medical unit treated and monitored patients by the same oncologist.
Candidates for surgery and radiotherapy were referred to other hospitals for treatment, as our hospital does not offer this specialty.
From the records of patients who attended during the study period (2004-2014), the following information was gathered: date of diagnosis, age at appointment, gender and tumor histology (2004 WHO classifi cation). [8] Immunohistochemical markers (CK7, CK20, TTF-1 and p63) have been used at our hospital since 2007. [9] [10] [11] Tumor-node-metastasis ( TNM) stage by American Joint Committee on Cancer, Seventh Edition, was also utilized. [12] Patients with non-small cell lung cancer (NSCLC) were classifi ed by clinical parameters (clinical TNM), with small cell lung cancer (SCLC) also being classifi ed by TNM system. Dates of death were included, although when the date was undefi ned based on records, family was contacted. We reported the cause of death (death without disease; death with the disease). For patients still alive, the last follow-up was recorded as July 15, 2014. Survival time was calculated from the time of histological/radiological diagnosis. Patients had to have at least 1-month of follow-up.
Genetic testing, when performed, was for the epidermal growth factor receptor (EGFR) and other NSCLC-driving mutations. Screening for drug-sensitive EGFR mutations was conducted as part of a clinical assistance program, since June 2010, by peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based testing. Those who were not analyzed have been recorded as "not determined." Anaplastic lymphoma kinase (ALK) translocations were determined via fl uorescence in situ hybridization since June 2012. We did not study K-RAS mutations as part of the standard of care. Other aspects relevant to prognosis, such as the Eastern Cooperative Oncology Group score, treatment type, weight loss and smoking habits, were not recorded.
Statistical analysis
Results were expressed as means (standard deviation) and percentages. The relationships between different variables were evaluated. Statistics of contrasts, such as Chi-square, Mann-Whitney U-test or Kruskal-Wallis H-test, were used for comparisons of two variables. Estimations are accompanied by 95% confi dence intervals. Statistical signifi cance was set at a value of P < 0.05. Survival time was defi ned as the period from the date of fi rst visit to the date of mortality or last follow-up. Survival date was updated on July 15, 2014. In addition to the estimation of the survival rates by Kaplan-Meier method, patients were classifi ed into groups for comparison of their demographic and clinical characteristics as follows: gender, stage and histology. The same classifi cation was made for comparison of survival by year of diagnosis. Statistical analysis was performed using SPSS 12.
Study approval
The institution's ethical review board approved the study, and all patients provided written informed consent and gave permission before study entry to collect their clinical data for scientifi c purposes and publication.
Results
From January 1, 2004 to June 15, 2014, 701 patients were included at our series. Patients' characteristics are shown in Table 1 . We found an aged and male-predominant population (mean age: 67.6; 91.4% were male). 
Trends in gender by years
Only 59 (8.4%) patients were women [ Figure 1 ]. This low incidence was maintained across the years. We found a slight increase in women patients from 2010 to 2014 (P = 0.045). A ratio of almost 9:1 was maintained across the years. Female was related to younger age (P = 0.001), histology (ADC and small cell: P = 0.001), Stage IV (P = 0.02) [ Table 2 ].
Distribution by histological type
Histology related to smoking habit (SCLC and squamous cell lung cancer [SQCLC]) was predominated (121, 17.2% SCLC and 291, 41.5% SQCLC) [ Table 1 ].
Histologic trends by years
Trends through years showed a decline in SQCLC.
Although it was the main histology (incidence 37-45%), in later years, we found a signifi cant increase in ADC (32-40%) and a signifi cant and relevant increase in SCLC (last date near 20-25%) (P = 0.0001) [ Figure 2 ].
Stage trends by years
A tendency of an increase of earlier stages in the last years is shown in Figure 3 (P = 0.063 
Overall survival
Survival time was ascertained for all patients. Median overall survival (OS) for the entire series was 
Longer survival for Stage IV
Median OS for Stage IV patients was nearly 12 months and there were 100 patients with median OS of 12 months or more in this stage (24.6%). Median OS for those with < 12 months was only 5 months (4.6-5.3). For those surviving more than 1-year, OS was 26.5 months (23-30 range) (P = 0.0000). Prognostic factors related to longer survival with Stage IV were: female (P = 0.000), histology (ADC and neuroendocrine), and EGFR mutation for men only. Longer survival was statistically signifi cant, related to the year of diagnosis (2011 and 2012, P = 0.006).
Discussion
After the analysis of our 10 years database, we have found that lung cancer in our region remains a disease of smoker men. The predominant cause of lung cancer in men is active cigarette smoking. From our date, we cannot check the hypothesis that women are more susceptible than men to smoking-induced lung cancer. What we have found is that young women are smokers and elderly are non-smoker lung cancer patients. However, aspects of lung cancer in men and women continue to indicate potential male and female differences in the etiology of lung cancer, which based on several observations. Among non-smokers, women have higher lung cancer incidence rates than men. There are different clinical characteristics of lung cancer in women compared with men, such as the higher percentage of ADC in non-smokers, the greater prevalence of EGFR gene mutations in ADCs among non-smokers, and better prognosis. Our study reports on the variation in lung cancer patterns and trends across 10 years in a single center registry. [13] [14] [15] [16] Special attention has been given to gender, histology, stage and survival. We found a high incidence of lung cancer in men that maintained across the years. The majority of patients were diagnosed at an advanced stage and OS remained The predominance of lung cancer men in our series has been reported yet in Spain. [17] [18] [19] [20] The current male-to-female ratio in the USA is close to one. [21, 22] Our ratio of males to females with lung cancer is still high, [23] [24] [25] similar to other spainish rural areas. In any case, the male-to-female ratio is still substantially higher in Spain (8.5 in 2003) [26, 27] than in other Western countries, where it varies between 1.3 and 4.5 likely due to the much more rare habit of smoking in women than in men. [2, 4, 28] It is known that over 95% of Spanish male lung cancer patients smoke.
[3] Anti-tobacco policies had been introduced in Spain only in recent years. [20, 28] So, the reason for the predominance of male patients in our area could be explained by tobacco use. We have not specifi ed tobacco habits of our series, but almost 90% were likely current or former smokers. [29] There is a popular type of manufactured cigar, named "caliqueño," without fi lter, and not low-tar so that smokers maintained the profi le of tobacco users (not inhaling deeper, so generating central tumors, as squamous and small cell cancers).
In our rural area, in the non-smoking population, the incidence of lung cancer is higher among women. [30] For lung cancer women, those elderly, always non-smokers, developed ADC. The younger female patients, usually smokers, developed lung cancer related to smoke, such as SCLC. Recent fi ndings also suggest that women may be somewhat more susceptible to the carcinogenic effect of tobacco, [6, 31] although this remains a matter of debate.
Respect to histology, in our area we found a predominance of squamous and small cell cancer through the years. This distribution is different from those worldwide. Worldwide, the trend is toward an increase in the proportion of adeno-and a decrease in squamous cell carcinomas, although the rate of change varies across different geographical areas. [18] This change has mainly been attributed to the decline in the number of smokers and the more widespread consumption of fi ltered cigarettes in USA. In spite of the proportional decline over the last 20-30 years, squamous cell carcinoma is still the most common histological subtype among males in several European countries (37% in France, 44% in Poland and 45% in Holland). [5] In Spain, squamous cell carcinoma is the most common subtype with percentages varying between 24% and 50% in local and regional registries and SCLC still accounts for some 20% of cases in most Spanish registries. In United States, ADC (40%) is the most common subtype, followed by squamous cell carcinoma (25%) and large cell carcinoma (10%). [26] Incorporation of women into tobacco use worldwide and smoking fi ltered cigarettes that are low in nicotine could partially explain the rise in the rate of ADC worldwide. [28, 32] We found a relationship between histology and gender as squamous and small cell cancers prevailed in males and ADC in females. In our series as in most series, Stage IV remained the most common stage. [26] However, our series distribution by stage has changed through the years, with a decrease in Stage IV and increase in Stage III. We have not implemented yet the lung cancer screening. We can not explain this tendency change on stage across years.
OS for our entire series remained low. Overall 5-year survival rate for all stages of lung cancer, is 17% worldwide.
[27] Our 5-year OS for all series was 15% and the only factor related to survival was stage. For Stage IV, a median increase of 2 months was seen through years with a better prognosis in the latest years. When we analyzed Stage IV patients, we found a double distribution. Those who did not survive more than 12 months had a median OS of only 5 months. Although long survival in lung cancer has been described and is a matter of interest, shorter survival patients are still more common and should be a matter of study to know why there are so many patients with this discouraging OS. For long survival at our database, the main factor was a molecular prognostic factor (EGFR mutation). There was an interaction between female gender, ADC histology and EGFR mutation, as women with ADC were nearly all mutated. Our series had a low percentage of patients with EGFR activating mutations. However, most patients had not been tested for EGFR status. Probably, the low rate of men with ADC EGFR mutations (only 1.7%) could be explained by the high rate of smoking habit in this population.
Our work has some weak points. Despite the importance of a long follow-up time, our work is not as accurate as it could have been. In fact, first we presented a hospital-based cancer registry of outpatient service; therefore a selection bias could not be excluded. Population-based cancer registries should be preferred. However, in Spain, in spite of many efforts [17] [18] [19] [20] not more than 26% of the Spanish population (28% in the case of childhood cancer) is covered by cancer registries and the distribution of them is not random. [22] Second, we have not considered other prognostic factors, such as performance status or treatment. Thus, we must be cautious with conclusions. Treatment could be one of the explanations of why women with ADC had no differences on survival depending on EGFR status. In our country, lung cancer patients have access to EGFR TKI on the second and third line, regardless on EGFR status. [33] and most of these patients may have received EGFR TKI. Despite this bias and weaknesses, we believe on the value of having own clinical real date if all admit that cancer is an individual disease, and probably, lung cancer is different according to epidemiology characteristics.
Conclusion
This single center analysis suggests that at least at our region, lung cancer remains a men disease and tobacco-related cancer. Advances and improvements on OS seemed to have been achieved only in those tumors unrelated to smoking (non-smoker women EGFR mutated patients). Efforts to reduce tobacco use and carry on with improvement in treatment could modify this disappointing survival for our patients.
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